Joy Gianvittorio, MD
Family Medicine · Virginia Beach, VANPI 1285609768
Payments from drug & device makers
Across 292 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$496
- Pfizer$447
- Lilly USA, LLC$416
- GSK$354
- AstraZeneca$308
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,28899%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $1,013 |
| Novo Nordisk | 29 | $496 |
| Pfizer | 22 | $447 |
| Lilly USA, LLC | 25 | $416 |
| GSK | 17 | $354 |
| AstraZeneca | 19 | $308 |
| Boehringer Ingelheim | 15 | $266 |
| Amgen | 10 | $257 |
| Otsuka America Pharmaceutical, Inc. | 11 | $250 |
| Johnson & Johnson | 7 | $141 |
| Abbott | 6 | $134 |
| Sanofi Pasteur Inc. | 6 | $130 |
| Astellas Pharma US Inc | 6 | $110 |
| Idorsia Pharmaceuticals US Inc | 5 | $99 |
| Eisai Inc. | 3 | $92 |
| Medtronic | 2 | $83 |
| Boston Scientific | 3 | $76 |
| Merck | 3 | $73 |
| Mylan Specialty L.p. | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Scpharmaceuticals Inc. | 2 | $56 |
| Currax Pharmaceuticals LLC | 2 | $40 |
| Novartis | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Biogen | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Viatris Specialty LLC | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $24 |
| Harmony Biosciences LLC | 1 | $24 |
| Corcept Therapeutics | 1 | $20 |
| Kaleo, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Stryker | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$115
How this compares
$5,321 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $60,360 |
| JanuviaSitagliptin Phosphate | 35 | $42,119 |
| FarxigaDapagliflozin Propanediol | 48 | $39,505 |
| EliquisApixaban | 31 | $28,505 |
| OzempicSemaglutide | 22 | $24,486 |
| MounjaroTirzepatide | 23 | $21,391 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,475 |
| MyrbetriqMirabegron | 16 | $8,288 |
| Carvedilol ErCarvedilol Phosphate | 11 | $5,586 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,023 |
| Atorvastatin Calcium | 457 | $3,889 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $3,242 |
| Rosuvastatin Calcium | 250 | $3,210 |
| Valsartan | 90 | $2,363 |
| Levothyroxine Sodium | 186 | $2,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $266 | $60,36058 claims |
| MerckJanuvia | $73 | $42,11935 claims |
| AstraZenecaFarxiga | $308 | $39,50548 claims |
| PfizerEliquis | $447 | $28,50531 claims |
| Novo NordiskOzempic | $496 | $24,48622 claims |
| Lilly USA, LLCMounjaro | $416 | $21,39123 claims |
| GSKTrelegy Ellipta | $354 | $14,47519 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $8,28816 claims |
| AbbVieSynthroid | $1,013 | $2,18856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Virginia Beach
- Gregory HaaseVirginia Beach$517K
- Ted KubickiVirginia Beach$159K
- Jim-David GaglioneVirginia Beach$24K
- Michael CharlesVirginia Beach$18K
- Glenn McDermottVirginia Beach$18K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.